These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33114603)

  • 1. Kynurenine Promotes RANKL-Induced Osteoclastogenesis In Vitro by Activating the Aryl Hydrocarbon Receptor Pathway.
    Eisa NH; Reddy SV; Elmansi AM; Kondrikova G; Kondrikov D; Shi XM; Novince CM; Hamrick MW; McGee-Lawrence ME; Isales CM; Fulzele S; Hill WD
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Human Osteoclast Differentiation by Kynurenine through the Aryl-Hydrocarbon Receptor Pathway.
    Kim SY; Oh Y; Jo S; Ji JD; Kim TH
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
    Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration and Duration of Indoxyl Sulfate Exposure Affects Osteoclastogenesis by Regulating NFATc1 via Aryl Hydrocarbon Receptor.
    Liu WC; Shyu JF; Lim PS; Fang TC; Lu CL; Zheng CM; Hou YC; Wu CC; Lin YF; Lu KC
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nuclear Receptor AhR Controls Bone Homeostasis by Regulating Osteoclast Differentiation via the RANK/c-Fos Signaling Axis.
    Izawa T; Arakaki R; Mori H; Tsunematsu T; Kudo Y; Tanaka E; Ishimaru N
    J Immunol; 2016 Dec; 197(12):4639-4650. PubMed ID: 27849171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
    Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
    Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic Effects of Indoxyl Sulfate on Osteoclastogenesis and Osteoblastogenesis.
    Shyu JF; Liu WC; Zheng CM; Fang TC; Hou YC; Chang CT; Liao TY; Chen YC; Lu KC
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression.
    Kim EJ; Lee H; Kim MH; Yang WM
    BMC Complement Altern Med; 2018 Oct; 18(1):270. PubMed ID: 30285722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evaluation of imidazole-derived bisphosphonates on receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and function.
    Lin J; Peng Y; Liu Q; Li K; Lv G; Seimbille Y; Huang G; Gao F; Qiu L
    Chem Biol Drug Des; 2021 Jan; 97(1):121-133. PubMed ID: 32735740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression.
    Lee H; Lee K; Lee S; Lee J; Jeong WT; Lim HB; Hyun TK; Yi SJ; Kim K
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.